Koch Industries Inc. lifted its holdings in shares of Inogen, Inc (NASDAQ:INGN) by 19,485.8% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 657,102 shares of the medical technology company’s stock after purchasing an additional 653,747 shares during the quarter. Koch Industries Inc. owned about 3.17% of Inogen worth $650,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of INGN. BlackRock Inc. boosted its holdings in shares of Inogen by 145,976.1% during the first quarter. BlackRock Inc. now owns 2,110,800 shares of the medical technology company’s stock worth $163,711,000 after purchasing an additional 2,109,355 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Inogen by 24.9% during the second quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after purchasing an additional 301,737 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Inogen by 77.4% during the second quarter. New York State Common Retirement Fund now owns 389,206 shares of the medical technology company’s stock worth $37,138,000 after purchasing an additional 169,778 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Inogen by 166.2% during the second quarter. Russell Investments Group Ltd. now owns 196,886 shares of the medical technology company’s stock worth $18,786,000 after purchasing an additional 122,913 shares during the last quarter. Finally, FMR LLC boosted its holdings in shares of Inogen by 56.2% during the first quarter. FMR LLC now owns 324,200 shares of the medical technology company’s stock worth $25,145,000 after purchasing an additional 116,600 shares during the last quarter.

Shares of Inogen, Inc (INGN) traded down 0.42% on Friday, reaching $94.38. The company had a trading volume of 89,762 shares. The company has a 50 day moving average price of $98.11 and a 200 day moving average price of $90.78. Inogen, Inc has a 52-week low of $50.24 and a 52-week high of $105.35. The stock has a market capitalization of $1.96 billion, a PE ratio of 81.93 and a beta of 0.99.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The company had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. During the same period in the prior year, the company earned $0.25 earnings per share. The business’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, equities research analysts anticipate that Inogen, Inc will post $1.21 earnings per share for the current year.

WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/14/koch-industries-inc-has-650000-stake-in-inogen-inc-ingn.html.

In other Inogen news, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $91.67, for a total transaction of $1,283,380.00. Following the completion of the sale, the director now directly owns 7,808 shares in the company, valued at $715,759.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $93.88, for a total transaction of $234,700.00. The disclosure for this sale can be found here. Insiders have sold 62,167 shares of company stock valued at $5,960,186 over the last 90 days. Corporate insiders own 5.31% of the company’s stock.

Several equities research analysts have recently issued reports on INGN shares. Zacks Investment Research cut Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 11th. J P Morgan Chase & Co raised their price objective on Inogen to $102.00 and gave the stock an “overweight” rating in a report on Monday, June 26th. Piper Jaffray Companies restated a “hold” rating and set a $90.00 price objective on shares of Inogen in a report on Tuesday, September 12th. Needham & Company LLC restated a “buy” rating and set a $108.00 price objective on shares of Inogen in a report on Friday, September 1st. Finally, BidaskClub upgraded Inogen from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 8th. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $90.80.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.